Anticoagulants Market Size To Hit USD 67.54 Bn By 2032

The global anticoagulants market size was valued at USD 30.84 billion in 2023 and is projected to hit around USD 67.54 billion by 2032, growing at a registered CAGR of 9.1% from 2023 to 2032.

Key Points:

By indicated disease, the pulmonary embolism segment has contributed 75% market share in 2022.
By drug category, the factor Xa inhibitor segment accounted for 56% market share in 2022.
By distribution channel, the hospital pharmacy segment made up 50% market share in 2022.
North America region accounted for 58% market share in 2022.

COVID-19 pandemic is foreseen to have a noticeable impact on the anticoagulant industry due to the growing pace of research. Clinical trials are presently under process to evaluate the potential of anticoagulants in COVID-19 patients. As a result, the COVID-19 pandemic will have direct as well as indirect implications for the market forecasted. Moreover, as per World Health Organization Update in January 2021, patients infected with COVID-19, both suspected and confirmed, must be provided with follow-up facilities with a minimum dose of anticoagulants. As a result, the demand for anticoagulants will grow during the course of the pandemic.

Full Report is Ready | Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1796

Regional Snapshots

North America is foreseen to hold a vast market share in the global anticoagulants market due to the high consumption of innovative products, and the increasing risk of cardiovascular disorders in this region. For example, as per the American Heart Association Research in October 2021, approximately 2,299 Americans loose their lives due to cardiovascular diseases, which accounts to an average of a single death every 38 seconds. The Asia-Pacific region grants lucrative chances for companies operating in the anticoagulants market, attributable to its growing population support, rising risk of heart related disease and VTE, improving diagnosis, developing economies and growing demand for improvised treatment.

Report highlights

On the basis of the indicated diseases, the pulmonary embolism segment is expected to have a dominant market share during the forecast period. The introduction of a successful anticoagulant which is Eliquis is indicated for this condition which is expected to drive the market. Pulmonary embolism is a blood clot that occurs in the pulmonary arteries of the lungs and blocks the blood flow. It is a life threatening condition which could lead to other conditions like the deep vein thrombosis. Due to increasing prevalence of the pulmonary embolism which is caused by heart disease, obesity or cancer the market for anticoagulants is expected to grow during the forecast period.
On the basis of the administration route of the drugs, the oral segment is expected to have the largest market share during the forecast period. As new and prominent products are launched in this segment the segment is expected to grow. The hospital pharmacies distribution segment is expected to have a larger market share during the forecast period. The hospital pharmacy segment shall grow as the anticoagulants are risky and they are prescribed only after a thorough diagnosis.

Table of Contents

Report Scope of the Anticoagulants Market

Report Coverage	Details
Market Size in 2023	USD 30.84 Billion
Market Size by 2032	USD 67.54 Billion
Growth Rate from 2023 to 2032	CAGR of 9.1%
Largest Market	North America
Fastest Growing Region	Asia Pacific
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Indication of Disease, Administration Route, Drug Class, Distribution Channel, Geography

Anticoagulants Market Dynamics

Drivers

Rapid urbanization is considered as a cause to an increase in the cases of chronic diseases and technological developments in the innovation of anticoagulant products. The global increase of ischemic heart disease is foreseen to exceed 1,840 per 100,000 by the year 2030. However, increasing prevalence of chronic diseases, unhealthy ways of living adopted by people, and growing shift to novel oral anticoagulants (NOACs) act as the major driving forces in anticoagulants market. Further, technological developments in the innovation of anticoagulant medicines are foreseen to propel the market.

Restraints

The stringent regulatory guidelines and increased risk of side effects from treatment are expected to curtail market size during the forecast period. Increasing health awareness about the side effects like malena, hemoptysis, epistaxis, menorrhagia, hematuria and bleeding gums have proved to be a restraining factor for the growth of the anticoagulant products market. With advancements in technology and quality of anticoagulants, the increasing cost of the drugs is also posing to be a challenge for the growth of the market.

Opportunities

Rising adoption of novel oral anticoagulants (NOACs), and increasing awareness of NOACs in developing nations prove to be a great opportunity for the anticoagulant products market. Surge in demand for novel treatment along with rising geriatric population are also foreseen to fuel the market growth. Growing prevalence of cardiovascular disorders and venous thromboembolism (VTE) has offered a good opportunity for the market to grow during the forecast period.

Challenges

Increasing health awareness has made people careful with the use of chemically compounded medicines owing to the side effects produced by them over a period of time, which proved to challenge the growth of the market. The rise in the competition among the manufacturers and the diversity of the products has also proved to be a challenge for the growth of the anticoagulant products market during the forecast period.

Key Developments

Xia inhibitor Asundexian, an oral factor of Bayer was permitted fast track status by the Food and Drug Administration of the United Stated in February, 2022. This drug was in second phase of testing which could provide safety benefits over present drugs.
Anticoagulation treatment was being used by the Stony Brook Study to discover D-Dimer levels lowered fatality in highly diseased patients of the COVID-19, in February, 2021.
An agreement was signed by Mylan N.V. to acquire Aspen Pharmacare Holdings to get aid in positioning for one of the largest suppliers of injective anticoagulants to customers in the Europe region. The agreement was signed in September, 2020.
Aspen Pharmacare Holdings received an investment of $756 million from Mylan to bolster its product offerings, in September, 2020.

Competitive Landscape

The global anticoagulants market is in mature state, and has a large existence of generics specifically for old product launches. The entry of new players is a bit difficult as they have to follow all the formulations of drugs made by various associations, and cannot break them at all. A few market players have a significant market share and have their presence all around the world.

Key players

Johnson & Johnson
Bristol-Myers Squibb Company
Daiichi Sankyo Company
Bayer AG
Boehringer Ingelheim GmbH
Aspen Holdings
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi S.A.
Portola Pharmaceuticals

Segments covered in the report

By Indication of disease

Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT)
Atrial Fibrillation
Heart Attacks
Others

By Administration Route

Oral
Injectable

By Drug Class

NOACs
- Eliquis
- Bevyxxa
- Xarelto
- Savaysa & lixiana
- Pradaxa
Heparin & LMWH
Vitamin K Antagonist
Others

By Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacy
Others

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa